スニチニブ
gov/pmc/articles/PMC3646307/.
↑ Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. | CureHunter
↑ 95%信頼区間
↑ “Pfizer Scores New Approval for Sutent in Europe”. (2010年12月2日). http://www.genengnews.com/gen-news-highlights/pfizer-scores-new-approval-for-sutent-in-europe/81244326/
↑ FDA approves Sutent for rare type of pancreatic cancer
↑ "Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma"
↑ “Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition”. Arch Dermatol 144 (11): 1525–6. (November 2008). doi:10.1001/archderm.144.11.1525. PMID 19015436. オリジナルの2011-07-25時点におけるアーカイブ。. https://web.archive.org/web/20110725002034/http://archderm.
34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=34252.
↑ “A Phase 2 Study to Evaluate the Efficacy of SU11248 in Patients with Unresectable Neuroendocrine Tumors”. Presented at ASCO 2005. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=33268.
↑ “In Gene Sequencing Treatment for Leukemia, Glimpses of the Future”. 2021年12月3日閲覧。
↑ Writer, GEN Staff (2011年5月23日). “FDA Expands Sutent Label to Include Pancreatic Neuroendocrine Tumors” (英語). GEN - Genetic Engineering and Biotechnology News. 2021年12月5日閲覧。